Anne-Laure Pointet Selected Research

Adenocarcinoma

1/2020	Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
1/2020	Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anne-Laure Pointet Research Topics

Disease

2	Biliary Tract Neoplasms (Biliary Tract Cancer) 12/2020 - 01/2019
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 01/2019
2	Adenocarcinoma 01/2020 - 01/2020
2	Neoplasms (Cancer) 06/2015 - 02/2015
1	Disease Progression 01/2020
1	Colonic Neoplasms (Colon Cancer) 06/2015

Drug/Important Bio-Agent (IBA)

4	Gemcitabine FDA Link 01/2020 - 01/2019
3	130-nm albumin-bound paclitaxelIBA 01/2020 - 01/2019
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2019 - 06/2015
1	PlatinumIBA 12/2020
1	folfirinoxIBA 01/2019
1	Cisplatin (Platino)FDA LinkGeneric 01/2019
1	Fluorouracil (Carac)FDA LinkGeneric 06/2015
1	XELOXIBA 06/2015
1	Immunologic Factors (Immunomodulators)IBA 02/2015
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2015

Therapy/Procedure

4	Therapeutics 01/2020 - 02/2015
3	Drug Therapy (Chemotherapy) 12/2020 - 01/2019
1	Adjuvant Chemotherapy 06/2015